FINNENCE ▪ THE WIRE FILE
THE WIRE · № 67129
News■ Unclear/unknown
Lycia seeks IPO for antibody degraders as TRexBio, Retension set terms
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES3
STORY SIZESTANDALONE
FIRST SEEN2026-10-06 08:21 UTC
LAST UPDATE2026-10-06 08:21 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
New biotech IPO filings add primary-market supply and signal risk appetite, but terms are unset and pricing is uncertain.
Biotech IPO pipeline reopens, testing investor demand
CATALYST TO WATCH
IPO pricing and first-day trading
MAIN RISK
Weak pricing could chill biotech issuance
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Peer-Reviewed Preclinical Study Demonstrates Regenerative Potential of Spinogenix's Tazbentetol for Treating Diabetic Retinal Neuropathy2026-10-06 12:30 UTC
New Peer-Reviewed Preclinical Study Demonstrates Regenerative Potential of Spinogenix's Tazbentetol for Treating Diabetic Retinal Neuropathy2026-10-06 12:30 UTC
→CORRELATIONshares Healthcare
Lupus Research Alliance Awards $3 Million to Transform How Lupus Treatment Response is Predicted and Personalized2026-10-06 12:32 UTC
Lupus Research Alliance Awards $3 Million to Transform How Lupus Treatment Response is Predicted and Personalized2026-10-06 12:32 UTC
→CORRELATIONshares Healthcare
Russian lab worker's suspected plague death leaves some questions unanswered2026-10-06 12:36 UTC
Russian lab worker's suspected plague death leaves some questions unanswered2026-10-06 12:36 UTC
←CORRELATIONshares Healthcare, IBB
In test of investors' appetite, Lilly-connected TRex Bio plots $153 million IPO2026-10-05 19:31 UTC
In test of investors' appetite, Lilly-connected TRex Bio plots $153 million IPO2026-10-05 19:31 UTC
←CORRELATIONshares Healthcare, IBB
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations2026-10-05 20:30 UTC
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations2026-10-05 20:30 UTC
←CORRELATIONshares Healthcare
Report of Possible $5 Billion Takeover Bid Sends Option Care Health Stock Higher2026-10-05 21:16 UTC
Report of Possible $5 Billion Takeover Bid Sends Option Care Health Stock Higher2026-10-05 21:16 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.